~(123)I-MIBG心肌显像预测依那普利对扩张型心肌病患者治疗效果的临床价值

目的探讨123I-MIBG心肌显像在治疗前预测依那普利对扩张型心肌病(DCM)患者治疗效果的临床价值。方法对24例DCM患者于依那普利治疗前行早期(20min)及延迟(3h)123I-MIBG心肌显像,采用心/上纵隔(H/M)比和心脏放射性洗脱率(WR)作为相对半定量计数分析,与超声心功能参数进行对比。根据123I-MI-BG心肌显像延迟相的H/M分为3组延迟H/M≥1.7为组Ⅰ,1.5<延迟H/M<1.7为组Ⅱ,延迟H/M≤1.5为组Ⅲ。组Ⅰ和组Ⅱ在平均治疗4.5个月后重复以上检查。结果治疗前3组间超声心功能参数比较均无统计学差异。治疗后组Ⅰ的左室射血分数(LVEF)和左室收缩末径(LVDs)明显改善,早期H/M和延迟H/M均明显改善(P<0.05),而WR无明显变化。治疗后组Ⅱ的延迟H/M明显改善(P<0.05),而早期H/M和WR均无明显变化,心功能参数也无改善。组Ⅰ和组Ⅱ患者均能耐受依那普利治疗,而组Ⅲ患者均不能耐受依那普利治疗。结论123I-MIBG心肌显像在治疗前预测依那普利对DCM患者的治疗效果方面有一定价值。     

Total and free tissue factor pathway inhibitor in pregnancy hypertension.

OBJECTIVE: To clarify the role played by tissue factor pathway inhibitor (TFPI) in pregnancy hypertension. METHODS: Using enzyme-linked immunosorbent assays, hemostatic measurements were obtained for women with pre-eclampsia (n=51), nonproteinuric hypertension of pregnancy (n=62), postpartum pre-eclampsia 24 h after childbirth (n=31), and no hypertension (healthy pregnant controls, n=100). RESULTS: There was a significant increase in circulating free TFPI levels in women with pre-eclampsia (9.7+/-6.2 ng/mL) or nonproteinuric hypertension of pregnancy (8.3+/-5.3 ng/mL) compared with healthy controls (5.3+/-2.1 ng/mL). In women with pre-eclampsia the levels remained elevated after placental delivery (10.6+/-4.0 ng/mL). Free protein S levels were significantly higher in women with pre-eclampsia (40.0%+/-10.7%), nonproteinuric hypertension of pregnancy (37.1%+/-12.5%), or postpartum pre-eclampsia (39.3%+/-9.1%) than in healthy pregnant controls (32.2%+/-8.5%). CONCLUSION: Increased levels of the physiologically active free forms of TFPI and free protein S, 2 coagulation inhibitors, may protect women with pregnancy-induced hypertension from the risks of hemostatic activation.     

亚油酸对纤溶酶原激活物抑制剂-1表达的影响及其机制

目的探讨过氧化体增殖物激活型受体α（PPARα）的特异性激活物亚油酸对HepG2细胞1型纤溶酶原激活物抑制剂（PAI-1）mRNA表达及其活性的影响和在该基因转录调控中的作用机制.方法用不同浓度亚油酸为诱导因素刺激HepG2细胞,采用半定量RT-PCR法检测PAI-1mRNA水平,发色底物法检测PAI-1的活性变化.构建四个含PAI-1启动子序列从-804～＋17间不同长度片段驱动的荧光素酶报告基因质粒,体外瞬时转染HepG2细胞,检测荧光素酶的活性.结果与对照组相比,亚油酸组能使HepG2细胞PAI-1mRNA表达及蛋白活性显著升高（P＜0.05,P＜0.01）,且呈一定剂量依赖性;亚油酸诱导可使PAI-1转录活性显著升高（P＜0.01）;与转染质粒PAI-pGL3-A（-804/＋17）相比较,当转染质粒含有PAI-pGL3-B（-636/＋17）、PAI-pGL3-C（-449/＋17）时,荧光素酶活性显著降低（P＜0.01）;共转染PPARα表达质粒（PPARα-pSG5）的细胞在亚油酸诱导下PAI-1转录活性显著升高（P＜0.01）.结论亚油酸可以增加HepG2细胞PAI-1mRNA表达及其蛋白活性,调节PAI-1的基因转录,PPARα参与亚油酸对PAI-1基因的表达调控;在PAI-1启动子-804～-636、-449～-276区域内存在亚油酸作用的调控PAI-1基因表达的序列.     

参芪扶正注射液对淋巴细胞的作用

目的:观察参芪扶正注射液对淋巴细胞的作用.方法:用参芪扶正注射液处理Jurkat淋巴细胞,通过台盘兰染色计数和流式细胞计观察其对淋巴细胞的作用,用参芪处理过的淋巴细胞分别加入化疗药和肝癌细胞,观察两种细胞的反应.结果:参芪扶正注射液处理过的淋巴细胞,细胞增殖快,有较强的抵抗化疗药诱导凋亡的能力,杀伤肝癌细胞的能力增强.结论:参芪扶正注射液具有多方面的免疫调节作用.     

Characteristics of inhibitors in mild/moderate haemophilia A

Summary.  Patients with mild or moderate haemophilia A usually have a mild bleeding disorder requiring only occasional treatment with factor VIII (FVIII) concentrates. The frequency of inhibitor development in such patients has been the subject of several recent surveys, which significantly modified our appreciation of this complication. Studies of the anti-FVIII antibodies provided an explanation for the different bleeding phenotypes observed in mild/moderate haemophilia A patients with inhibitors. Antibodies distinguishing between the patient's mutant FVIII and the normal wild-type FVIII were characterized, in addition to antibodies inhibiting completely or only partially FVIII activity. T lymphocytes recognizing FVIII and likely involved in the development of the immune response to FVIII were successfully identified. The FVIII peptides recognized by those FVIII-specific cells bind to many major histocompatibility complex (MHC) class II molecules, which may provide an explanation for the lack of strong association between MHC haplotypes and inhibitor development. Although these studies have advanced our understanding of the conditions leading to inhibitor development, further work is required to determine whether the mode of FVIII administration significantly influences inhibitor development. Further studies of the genetic factors are also required to fully understand the mechanisms leading to inhibitor development in patients with mild/moderate haemophilia A.     

丙氨酸锗抗肿瘤活性及免疫效应

为探讨丙氨酸锗的抗肿瘤活性及免疫效应，本文进行了两个瘤株的抗肿瘤实验和免疫实验。结果表明：丙氨酸锗能明显延长移植Ｈ２２肝癌腹水型小鼠的生存时间，抑制Ｓ１８０肉瘤生长，提高Ｔ淋巴细胞＾８Ｈ－ＴｄＲ掺入指数，增强单核吞噬细胞吞噬功能。提示丙氨酸锗具有抗肿瘤活性，其抗肿瘤活性可能是通过提高机体免疫机能实现的。     

人血液酪氨酸蛋白激酶的研究——(Ⅲ)1—异丙基—6—氨基—噻吩骈[3,4—d]嘧啶—2,4—二酮对人淋巴细胞膜TPK活性的抑制作用

文报道了人工合成的1—异丙基—6—氨基—噻吩骈〔3,4—d〕嘧啶—2,4—二酮对人淋巴细胞膜TPK活性的抑制作用,IC_(50)约为300μmol/L。动力学实验结果表明,该化合物对TPK的抑制作用与ATP呈竞争性,而与多肽底物Poly(Glu—Ala—Tyr)_(6;3:1)呈非竞争性。放射自显影结果进一步证实了该化合物对TPK的抑制作用。     

不育患者血清精子蛋白17抗体的检测及临床意义

目的:检测抗精子抗体(AsAb)阳性不育患者血清中抗精子蛋白17(Sp17)的抗体,探讨该抗体在免疫性不育血清学诊断和免疫避孕方面的潜在应用价值。方法:用重组人Sp17作为抗原,ELISA法检测62例AsAb阳性血清中Sp17抗体阳性率及滴度,分析AsAb中抗Sp17的含量。结果:AsAb阳性血清中Sp17抗体阳性率为56.5%,男女之间差异无显著性。Sp17抗体占AsAb的(10.09±7.45)%,结果具有统计学意义(P<0.05)。结论:Sp17是重要的精子抗原组分,血清中Sp17抗体的检测可作为不育患者辅助诊断指标,同时也提示Sp17可能是一种免疫避孕候选抗原疫苗。     

具有靶向免疫抑制作用新型重组融合蛋白B7-2-PE40KDEL真核表达载体的构建及其生物效应

目的:构建B7-2-PE40KDEL的真核表达载体,探讨通过体内表达重组融合蛋白,特异性杀伤高表达CD28 T细胞,阻断B7∶CD28/CTLA4共刺激信号途径诱导免疫耐受的可能性.方法:以原核表达载体pRSETA-B7-2-PE40KDEL质粒为模板,采用PCR及酶切连接的方法构建真核表达载体pcDNA3.1/Zeo( )-B7-2-PE40KDEL.利用RT-PCR、Western 印迹及ELISA法从mRNA、蛋白质水平检测了B7-2-PE40KDEL在RPE-CHO真核细胞中的表达情况.采用MTT法对其特异性杀伤高表达CD28 T细胞的生物活性进行测定.结果:成功构建了pcDNA3.1/Zeo( )-B7-2-PE40KDEL真核表达载体,转染入RPE-CHO细胞后可转录翻译为重组融合毒素蛋白,相对分子质量约为71×103,平均106个转染细胞24 h表达0.23 μg/L.活性测定显示真核载体所表达的B7-2-PE40KDEL可特异性地抑制高表达CD28的人T淋巴细胞系,而对CD28阴性的人白血病细胞系的抑制率较低.结论:真核载体表达的B7-2-PE40KDEL具有良好的靶向性免疫抑制活性,为进一步开展其体内特异性防治移植排斥反应及自身免疫性疾病奠定了基础.     

松花粉抗衰老作用的实验研究

目的　观察松花粉的抗衰老作用。方法　用含松花粉的饲料喂养衰老小鼠 ,测定小鼠血清中超氧化物歧化酶 (SOD)、过氧化氢酶 (CAT)、谷胱甘肽过氧化物酶 (GSH Per)的活性 ,测定脑组织中丙二醛 (MDA)含量及脑组织和肝脏中的脂褐质 (Lf)含量 ,同时测定胸腺和脾脏的重量及网状内皮系统的吞噬功能。结果　松花粉能明显增加衰老小鼠血清中SOD、CAT、GSH Per活性 ,降低脑组织中MDA含量及脑组织和肝脏中的Lf含量 ,并增加胸腺和脾脏质量 ,提高网状内皮系统吞噬功能。结论　松花粉具有抗衰老作用